LMLindsey C. McVey

Lindsey C. McVey

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lindsey C. McVey has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Alexander Fletcher

    Developmental Endocrinology Research Group School of Medicine, Dentistry and Nursing Royal Hospital for Children University of Glasgow Glasgow UK

    1 shared publication
  • Avril Mason

    Department of Paediatric Endocrinology, Royal Hospital for Children, Glasgow, UK

    1 shared publication
  • Carolyn Abernethy

    Princess Royal Maternity Hospital, Glasgow

    1 shared publication
  • Helen Murray

    Department of Trauma and Orthopaedics, Queen Elizabeth University Hospital, Glasgow, UK

    1 shared publication
  • Malcolm Donaldson

    Developmental Endocrinology Research Group School of Medicine, Dentistry and Nursing Royal Hospital for Children University of Glasgow Glasgow UK

    1 shared publication
  • Mohammed Murtaza

    Developmental Endocrinology Research Group School of Medicine, Dentistry and Nursing Royal Hospital for Children University of Glasgow Glasgow UK

    1 shared publication

Latest Publications

  • Open Access

    1255 Less invasive surfactant administration (LISA) – outcomes and prognostic factors at a level 3 NICU

    by Lindsey C McVey, Carolyn Abernethy

    Background Less invasive surfactant administration (LISA) is delivered to neonates via a thin catheter, while the function of the glottis is maintained. There remains some debate as to which babies will benefit most from LISA, and the best threshold for undertaking this procedure. Objectives We aimed to review the LISA procedures undertaken at our centre, analyse patient and procedure characteristics, and evaluate outcomes, prognostic factors and procedure complications. Methods We reviewed all LISA procedures at our level 3 NICU from May 2018 (when LISA was introduced) until September 2020. Patients were identified on BadgerNet as having received surfactant, and case notes were reviewed to identify LISA patients. An audit proforma was completed retrospectively. Data were analysed using one-sample and two-sample Student’s t-tests where appropriate. Results LISA procedures were undertaken 86 times, including 7 repeat procedures. Median gestational age was 32+1 weeks [range: 24+5 to 41+1]; birth weight 1.72 kg [0.66 kg to 4.29 kg]; time from birth to first LISA procedure 5.7 hours [1.1 hours to 45.0 hours]; and FiO2 prior to LISA 0.35 [0.24 to 1.00]. Pre-medication included fentanyl [76 patients, 88%], atropine [14, 16%] and sucrose [7, 8%]. LISA was successful with a single procedure in 52 patients [66%], while 7 [9%] required repeat LISA and 20 [25%] required later intubation. Of the repeat LISA procedures, 5 [71%] were successful and 2 [29%] required later intubation. When successful LISA procedures were compared with those who required intubation, there was no difference in gestational age [p=0.94], birth weight [p=0.49], or time to first LISA [p=0.53]. FiO2 prior to LISA was lower in the successful group [mean 0.35 vs. 0.42, p=0.05]. To assess for a specific cut off in FiO2 than may predict treatment success, a ROC curve was analysed. The area under the ROC curve was small [0.64] and no specific cut off was possible. 72% had a documented desaturation or bradycardia during LISA. The vast majority responded to simple measures (pause, stimulation, chin lift, increased FiO2). Atropine rescue was required in 5 patients [5.8%]; naloxone in 2 [2.3%]; and an artificial airway (LMA or intubation) in 3 [3.5%]. Bronchopulmonary dysplasia was present in 27.5% of the patients born at < 32 weeks gestation in our unit, compared with 20.5% of LISA patients. Conclusions LISA was performed in a range of neonates from a gestational age of 24+5 to post-dates babies. Most were pre-medicated with fentanyl, although a proportion were managed with sucrose alone – as is becoming increasingly common internationally. LISA was successful in around two-thirds of our patients, and success rates were similar in our second LISA procedures. FiO2 prior to LISA was lower in the successful group, although no specific cut-off was possible. This suggests that a range of factors (such as antenatal steroids, gender, work of breathing) might also be important in determining likely response to LISA. Desaturation or bradycardia requiring significant intervention was rare. Bronchopulmonary dysplasia was less common in the LISA group than in our overall population, although this may be related to differences in baseline characteristics.

  • Open Access

    Skeletal disproportion in girls with Turner syndrome and longitudinal change with growth‐promoting therapy

    by Lindsey C. McVey, Alexander Fletcher, Mohammed Murtaza, Malcolm Donaldson, Sze Choong Wong, Avril Mason

    Objective: Short stature in Turner syndrome (TS) may be accompanied by skeletal disproportion. This retrospective study investigates growth and disproportion from early childhood to adult height.Study design: Data were collected from 59 girls prior to growth hormone (rhGH) treatment and in 30 girls followed up longitudinally. Standard deviation scores (SDS) for height (Ht), sitting height (SH) and sub‐ischial leg length (LL) were compared and a disproportion score (SH SDS – LL SDS) calculated.Results: In 59 girls, mean (SD) age 6.6 (2.1) years prior to rhGH treatment, LL SDS of −3.4 (1.1) was significantly lower than SH SDS of −1.2 (0.8) [p < .001]. In girls with Ht SDS < −2.0, disproportion score was > +2.0 in 27 (63%), cf eight (50%) with Ht SDS ≥ −2.0. For the longitudinal analysis, skeletal disproportion prior to rhGH was +2.4 (1.1) and +1.7 (1.0) on rhGH but prior to introduction of oestrogen [p < .001]. Disproportion at adult height was +1.1 (0.8), which was less marked than at the earlier time points [p < .001 for both comparisons]. Change in disproportion SDS over the first two years of rhGH predicted overall change in disproportion from baseline to adult height [R2 51.7%, p < .001].Conclusion: TS is associated with skeletal disproportion, which is more severe in the shortest girls and present in only half of those with milder degrees of short stature. Growth‐promoting therapy may improve disproportion during both the childhood and pubertal phases of growth. Change in disproportion status two years after starting rhGH helps predict disproportion at adult height.


  • Open Access

    Elective hip arthroplasty rates and related complications in people with diabetes mellitus

    by Lindsey C McVey, Nicholas Kane, Helen Murray, Rm Dominic Meek, S Faisal Ahmed

    Diabetes mellitus (DM), poor glycaemic control and raised body mass index (BMI) have been associated with postoperative complications in arthroplasty, although the relative importance of these factors is unclear. We describe the prevalence of DM in elective hip arthroplasty in a UK centre, and evaluate the impact of these factors. We analysed retrospective data for DM patients undergoing arthroplasty over a 6-year period and compared with non-diabetic matched controls (1 DM patient: 5 controls). DM was present in 5.7% of hip arthroplasty patients (82/1443). Postoperative complications occurred in 12.2% of DM patients versus 12.9% of controls (p = 1.000); surgical complications were present in 6.1% of those with DM and 2.4% of controls (p = 0.087), while medical complications occurred in 8.5% of DM patients versus 10.7% of controls (p = 0.692). Complications developed in 23.1% of DM patients with poor glycaemic control (HbA1c > 53 mmol/mol) versus 9.8% with good control (p = 0.169). In DM patients and controls combined, complications occurred in 16.3% of obese patients versus 10.0% of non-obese patients (p = 0.043). In the DM cohort, 13.7% of overweight patients had complications versus 0% with a normal or low BMI (p = 0.587). DM rates were lower than expected, and glycaemic control was good. Overall complication rates were unrelated to the presence of DM or to glycaemic control, although surgical complications were observed more frequently in those with DM and poor glycaemic control was uncommon within our cohort. Complications were more frequent in those with a higher BMI. Whether some patients with DM but without an increased risk of complications are currently being excluded from surgery requires exploration.